Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.

Lieneke F M AriënsJorien van der SchaftDaphne S BakkerDeepak BalakMargreet L E RomeijnTessa KouwenhovenMarijke KamsteegBarbara GiovannoneJulia DrylewiczCynthia Catalina Aurora van AmerongenEvelien M DelemarreEdward F KnolFemke van WijkStefan NierkensJudith L ThijsMarie L A SchuttelaarMarjolein de Bruin-Weller

Published in: Allergy (2019)

Treatment with dupilumab significantly improved disease severity and decreased severity-related serum biomarkers in patients with very difficult-to-treat AD in a daily practice setting.

Keyphrases

atopic dermatitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
primary care
prognostic factors
peritoneal dialysis
physical activity
young adults
childhood cancer